Medicinova Inc.

MNOV

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001226616


None

No letter

5 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $45.6M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	5 of 14
Graded from	filings received through Mar 10, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026
Last close	$1.45 2026-11-05; market equity $71.4M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 10, 2026

We are a biopharmaceutical company focused on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. Our current strategy is to focus our development activities on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS), and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 64.3						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						

Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(4.3%)	(6.6%)		64.3	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 0						
Solvency, sleeve percentile 47.0						
Twelve-month failure probability	not computable	0.08%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(18.54)	(0.37)		72.5	747	2025-12-31
Net debt to EBITDA	not computable	1.82x				
one or more required annual facts are missing						
Interest coverage	not computable	(4.51x)				
interest expense must exceed $100,000						
Current ratio	8.16x	2.94x		21.5	828	2025-12-31
Growth and financing, sleeve percentile 46.7						
Revenue growth, three-year compound	not computable	10.0%				
four consecutive annual observations are required						
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(15.0%)	2.2%		76.5	696	2025-12-31
Net share issuance, one year	0.4%	2.5%		16.9	630	2026-03-05

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	5 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	0.9%	(2.1%)	52
Distance from 52-week high	(57.7%)	(30.5%)	23
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(13.7%)	(1.0%)	28
Book value to price	0.52	0.29	70
Sales to price	0.01	0.30	5
Composite equity issuance, five years	1.1%	21.4%	27
Relative strength against the sector, log excess return	(0.16)	(0.19)	52

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$25.4M
Operating cash flow, four quarters	-$9.1M
Months of runway	33.5
Days since last periodic filing	86 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	$114,015

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$12.0M	2025-12-31	2026-03-10	10-K	26-100432
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$9.8M	2025-12-31	2026-03-10	10-K	26-100432
3	assets	us-gaap:Assets	$45.6M	2025-12-31	2026-03-10	10-K	26-100432
4	assets	us-gaap:Assets	$55.9M	2024-12-31	2026-03-10	10-K	26-100432
5	current assets	us-gaap:AssetsCurrent	$31.0M	2025-12-31	2026-03-10	10-K	26-100432
6	current liabilities	us-gaap:LiabilitiesCurrent	$3.8M	2025-12-31	2026-03-10	10-K	26-100432
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$438.7M	2025-12-31	2026-03-10	10-K	26-100432
8	operating income	us-gaap:OperatingIncomeLoss	-$13.3M	2025-12-31	2026-03-10	10-K	26-100432
9	book equity	us-gaap:StockholdersEquity	$41.6M	2025-12-31	2026-03-10	10-K	26-100432
10	liabilities	us-gaap:Liabilities	$4.0M	2025-12-31	2026-03-10	10-K	26-100432
11	operating income	us-gaap:OperatingIncomeLoss	-$13.0M	2017-12-31	2019-02-13	10-K	19-002835
12	interest expense	us-gaap:InterestExpense	$298	2017-12-31	2018-02-13	10-K	18-001957
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$409,657	2025-12-31	2026-03-10	10-K	26-100432
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0M	2023-12-31	2025-02-19	10-K	25-023301
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$4.0M	2021-12-31	2023-03-28	10-K/A	23-010297
16	revenue	us-gaap:Revenues	$802,580	2012-12-31	2013-03-28	10-K	13-132600
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$2,899	2025-12-31	2026-03-10	10-K	26-100432
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.6M	2024-12-31	2026-03-10	10-K	26-100432
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$895	2024-12-31	2026-03-10	10-K	26-100432
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$7.4M	2023-12-31	2025-02-19	10-K	25-023301
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$21,299	2023-12-31	2025-02-19	10-K	25-023301
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.9M	2022-12-31	2024-02-15	10-K	24-015920
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5,010	2022-12-31	2024-02-15	10-K	24-015920
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$20,099	2025-12-31	2026-03-10	10-K	26-100432
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$12.0M	2025-12-31	2026-03-10	10-K	26-100432
26	income tax	us-gaap:IncomeTaxExpenseBenefit	$5,994	2025-12-31	2026-03-10	10-K	26-100432
27	current assets	us-gaap:AssetsCurrent	$41.1M	2024-12-31	2026-03-10	10-K	26-100432
28	current liabilities	us-gaap:LiabilitiesCurrent	$3.0M	2024-12-31	2026-03-10	10-K	26-100432
29	assets	us-gaap:Assets	$66.3M	2023-12-31	2025-02-19	10-K	25-023301
30	assets	us-gaap:Assets	$74.2M	2022-12-31	2024-02-15	10-K	24-015920
31	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,221,246	2026-03-05	2026-03-10	10-K	26-100432
32	shares outstanding	dei:EntityCommonStockSharesOutstanding	49,046,246	2025-02-17	2025-02-19	10-K	25-023301

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.